OBJECTIVE: To examine the safety and efficacy of selective laser trabeculoplasty as primary treatment for @entity1 with @entity1538 . METHODS: Forty-five eyes of 31 @entity1 with @entity1538 or @entity2790 (intraocular pressure [IOP] >or=23 mm Hg on 2 consecutive measurements) underwent selective laser trabeculoplasty as primary treatment. All @entity1 underwent complete ophthalmic evaluation before and at intervals after treatment. This evaluation included visual acuity, slitlamp examination, ophthalmoscopy, gonioscopy, and visual field analysis. The IOP was measured 1 hour, 1 day, 1 week, and 1, 3, 6, 12, 15, and 18 months postoperatively. During the follow-up period, @entity1 were treated with topical antiglaucoma medications as required. RESULTS: Mean +/- SD decreased by 7.7 +/- 3.5 mm Hg (30%), from 25.5 +/- 2.5 mm Hg to 17.9 +/- 2.8 mm Hg (P<.001). Only 2 eyes (4%) did not respond to selective laser trabeculoplasty, and 3 eyes (7%) required topical medications to control their IOP at the end of the follow-up period. Forty eyes (89%) had a decrease of 5 mm Hg or more. Visual acuity, visual fields, and gonioscopic findings remained unchanged. Complications included conjunctival redness and injection within 1 day postoperatively in 30 eyes (67%). One hour after selective laser trabeculoplasty, an increase in IOP of more than 5 mm Hg was detected in 5 eyes (11%), while an increase in IOP between 2 and 5 mm @entity5332 was measured in 3 eyes (7%). CONCLUSION: Selective laser trabeculoplasty is effective and safe as a primary treatment for @entity1 with @entity2790 and @entity1538 .

Selective laser trabeculoplasty as primary treatment for XXXX : a prospective, nonrandomized pilot study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5332 :: ('D008628', 'Chemical') :: ['Hg'] @entity2790 :: ('MESH:D009798', 'Disease') :: ['ocular hypertension'] @entity1538 :: ('MESH:D005902', 'Disease') :: ['open-angle glaucoma']
@entity1538 :: (MESH:D005902,Disease) :: ['open-angle glaucoma']
